WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of “Moderate Buy” from Analysts

Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) have received a consensus rating of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and fourteen have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $32.5625.

Several equities research analysts have commented on the company. Leerink Partners restated an “outperform” rating on shares of WAVE Life Sciences in a research note on Monday, December 8th. Oppenheimer boosted their target price on WAVE Life Sciences from $24.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Wedbush raised their price target on shares of WAVE Life Sciences from $20.00 to $33.00 and gave the company an “outperform” rating in a report on Friday, December 12th. Bank of America began coverage on shares of WAVE Life Sciences in a research report on Thursday, February 5th. They set a “buy” rating and a $38.00 price target on the stock. Finally, UBS Group set a $32.00 price objective on shares of WAVE Life Sciences in a research note on Tuesday, December 16th.

WAVE Life Sciences Stock Down 0.9%

Shares of NASDAQ WVE opened at $12.68 on Monday. The stock has a market capitalization of $2.12 billion, a PE ratio of -16.91 and a beta of -1.78. The firm has a fifty day moving average of $15.20 and a 200-day moving average of $10.46. WAVE Life Sciences has a 52-week low of $5.28 and a 52-week high of $21.73.

Insider Activity

In other news, CFO Kyle Moran sold 3,588 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $48,258.60. Following the completion of the sale, the chief financial officer owned 134,385 shares in the company, valued at approximately $1,807,478.25. This trade represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Plc Gsk purchased 1,470,000 shares of WAVE Life Sciences stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average cost of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the transaction, the insider directly owned 18,245,691 shares in the company, valued at $346,668,129. This represents a 8.76% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 915,181 shares of company stock worth $13,612,581 in the last quarter. Insiders own 23.98% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC raised its position in shares of WAVE Life Sciences by 6,729.0% in the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after purchasing an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of WAVE Life Sciences by 645.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock worth $38,000 after buying an additional 1,942 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in WAVE Life Sciences in the fourth quarter valued at $82,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in WAVE Life Sciences by 32.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company’s stock valued at $138,000 after acquiring an additional 1,972 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in WAVE Life Sciences by 1,156.3% during the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after acquiring an additional 9,135 shares during the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.